

LITERATURA

1. Bishop KI, Isquith PK, Gioia GA, et al. Improved everyday executive functioning following profound reduction in seizure frequency with fenfluramine: Analysis from a phase 3 longterm extension study in children/young adults with Dravet syndrome. *Epilepsy Behav.* 2021;121:108024.

2. Hatini PG and Commons KG. A 5-HT1D-receptor agonist protects Dravet syndrome mice from seizure and early death. *Eur. J. Neurosci.* 2020;52:4370-4374. doi:10.1111/ejn.14776

3. Knupp KG, Scheffer IE, Ceulemans B, et al. Efficacy and Safety of Fenfluramine for the Treatment of Seizures Associated With Lennox-Gastaut Syndrome: A Randomized Clinical Trial. *JAMA Neurol.* 2022;79(6):55-564. doi:10.1001/jama-neurol.2022.0829

4. Knupp KG, Scheffer IE, Ceulemans B, et al. Fenfluramine provides clinically meaningful reduction in frequency of drop seizures in patients with Lennox-Gastaut syndrome: Interim analysis of an open-label extension study. *Epilepsia.* 2023;64(1):139-151. doi: 10.1111/epi.17431. Epub 2022 Nov 9. PMID: 36196777; PMCID: PMC10099582.

5. Lagae L, Sullivan J, Knupp KG, et al (FAiRE DS Study Group). Fenfluramine hydrochloride for the treatment of seizures in

Dravet syndrome: a randomised, double-blind, placebo controlled trial. *Lancet.* 2019;394(10216):2243-54.

6. Martin P, Czerwiński M, Limaye PB, et al. In vitro evaluation suggests fenfluramine and norfenfluramine are unlikely to act as perpetrators of drug interactions. *Pharmacol Res Perspect.* 2022;10:e00959.

7. Martin P, de Witte PAM, Maurice T, et al. Fenfluramine acts as a positive modulator of sigma-1 receptors. *Epilepsy & Behav.* 2020;105:106989. doi:10.1016/j.yebeh.2020.106989

8. Martin P, Reeder T, Sourbron J, et al. An emerging role for sigma-1 receptors in the treatment of developmental and epileptic encephalopathies. *Int J Mol Sci.* 2021;22:8416.

9. Nabbout R, Mistry A, Zuberi S, et al. Fenfluramine for treatment-resistant seizures in patients with Dravet syndrome receiving stiripentol-inclusive regimens: a randomized clinical trial. *JAMA Neurol.* 2020;77(3):300-8.

10. Reeder T, Martin P, Sourbron J, et al. Dual Activity of Fenfluramine (Fintepla®) as a Serotonin Receptor Agonist and Positive Sigma-1 Receptor Modulator: Implication for Disease Modification in Developmental and Epileptic Encephalopathies. Poster presented at the American Epilepsy

Society Annual Meeting, Chicago, IL, 2021;December 3–7.

11. Schoonjans A-N, Lagae L, Ceulemans B. Low-dose fenfluramine in the treatment of neurologic disorders: experience in Dravet syndrome. *Ther Adv Neurol Disord.* 2015;8: 328–38.

12. Sourbron J, Lagae L. Serotonin receptors in epilepsy: Novel treatment targets? *Epilepsia Open* 7. 2022; 31-246. doi:10.1002/epi4.12580

13. Sourbron J, Smolders I, de Witte P, et al. Pharmacological analysis of the anti-epileptic mechanisms of fenfluramine in scn1a mutant zebrafish. *Front Pharmacol.* 2017;8:191.

14. Sullivan J, Scheffer IE, Lagae L, et al. Fenfluramine HCl (Fintepla®) provides longterm clinically meaningful reduction in seizure frequency: Analysis of an ongoing open-label extension study. *Epilepsia.* 2020;61(11):2396-404.

15. Tupal S, Faingold CL. Serotonin 5-HT4 receptors play a critical role in the action of fenfluramine to block seizure induced sudden death in a mouse model of SUDEP. *Epilepsy Res.* 2021;177:106777.

16. Wirrell EC, Hood V, Knupp KG, et al. International consensus on diagnosis and management of Dravet syndrome. *Epilepsia.* 2022;63(7):1761-1777. doi: 10.1111/epi.17274. Epub 2022 May 12. PMID: 35490361; PMCID: PMC9543220.

ON-LINE KURZ

# Zaostřeno na syndrom Dravetové



**OBSAH KURZU**

- ▶ **Co víme o syndromu Dravetové u dospělých?** – prof. MUDr. Petr Marusič, Ph.D.
- ▶ **Na co ještě myslet u dětí?** – MUDr. Martin Kudr, Ph.D.
- ▶ **Cesta k diagnóze – dialog s genetikem** – MUDr. Katalin Štěrbová
- ▶ **Cesta k diagnóze – dialog s genetikem** – MUDr. Jana Zárubová
- ▶ **Cesta k diagnóze – dialog s genetikem** – MUDr. Markéta Vlčková, Ph.D.
- ▶ **Mechanismus účinku a protizáchvatová aktivita fenfluraminu** – MUDr. Ondřej Horák, doc. MUDr. Irena Doležalová, Ph.D.

**ODBORNÝ GARANT:**

doc. MUDr. Irena Doležalová, Ph.D.

**POŘADATEL:**

Společnost SOLEN, s. r. o.,  
ve spolupráci s I. neurologickou klinikou LF MU a FN u sv. Anny

Registrace  
**ZDARMA**

**TERMÍN**

květen 2024 až duben 2025

dostupný na  
online.solen.cz

